Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Dec
14
2011
San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 199... Read All »
Dec
13
2011
San Diego, CA – Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced... Read All »
Dec
08
2011
San Diego, CA  – Fate Therapeutics, Inc. announced today that the United States Patent and Trademark Office has granted a patent covering compositions that are broadly utilized throughout the field of induced pluripotent stem cell (iPSC) technology. U.S. Patent No. 8,071,369, entitled “... Read All »
Nov
16
2011
San Diego, California, November 16, 2011 – Fate Therapeutics, Inc. announced today that the United States Patent and Trademark Office has granted a patent covering the novel stem cell modulator commonly known as Thiazovivin. U.S. Patent No. 8,044,201 entitled "Stem Cell Cultures" claims Th... Read All »
May
09
2011
Osaka, Japan & San Diego, California, May 9, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) and Fate Therapeutics, Inc. (“Fate”) jointly announced today that Takeda’s corporate venture arm, Takeda Ventures, Inc. (Palo Alto, California, “TVI”) has made an equity investment in Fate ... Read All »
Feb
21
2011
San Diego, CA – February 21, 2011 – Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii (Abstract Number: 198; entitled, “Ex Vivo Treatment of Hematopoiet... Read All »
Feb
21
2011
San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics announced that Paul A. Grayson, who has been president & CEO since April 2008, is ... Read All »
Oct
14
2010
San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwide ... Read All »
Jun
28
2010
San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today that the Company received Red Herring’s North America 100 award, a prestigious list honoring the year’s most promising private and innovative companies from the North American business region. The nominees were evaluated by the Red Herring editorial tea... Read All »
May
11
2010
San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company’s Scientific Advisory Board (SAB). The new SAB members bring deep experience and expertise in systems biology, epigenetics, gene regulation, expression analysis and adult stem cell and developmental bi... Read All »
May
10
2010
San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of Tom Novak, Ph.D., as vice president of research and drug discovery. Dr. Novak brings to Fate more than 15 years of experience working with large pharmaceutical companies, including Roche and Wyeth, to apply tra... Read All »
Apr
08
2010
San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therap... Read All »
Feb
26
2010
San Diego, CA – Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review’s 2010 TR50, the first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the field... Read All »
Feb
04
2010
San Diego, CA – Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled “Methods for Reprogramming Somatic Cells.” Upon issuance, the patent will cover foundational induced plur... Read All »
Dec
21
2009
San Diego, CA – Fate Therapeutics, Inc. announced today that the Company’s iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Sullivan. These notable awards recognize Fate Ther... Read All »
= add release to Briefcase